Tirzepatide’s effects on fatty liver disease linked to metabolism: results from phase II trials and future outlook

Tirzepatide achieved MASH resolution with no worsening of fibrosis in a significantly higher percentage of patients than placebo.

• Tirzepatide is associated with improved glucose metabolism and reduced food intake.
• In the SYNERGY-NASH phase 2 study, a higher percentage of patients treated with tirzepatide experienced MASH resolution compared to those receiving placebo.
• More patients in the tirzepatide group achieved a 1-stage or greater improvement in fibrosis without worsening MASH, though this was not the primary focus of the study.
• Noninvasive biomarkers of fibrosis did not show significant improvement in either treatment group.

Simplified